Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ishina Balwani"'
Autor:
Amy Becker, Troy Luster, Ishina Balwani, Erica Del Aguila, Nishit Patel, Birgit Schultes, Justin Oh, Nachiket Narendra Shevale, Ivy Dutta, Nazia Ali, Nithila Saravanan, James Peter, Yurui Guo, Hanan Dahche, Jingyu Peng, Bo Han, Dai Liu, Aaron Prodeus, Michael Lam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d0586343d6944ae08f1902d3de3506bc
Autor:
Jeff Jones, Amy Becker, Troy Luster, Ishina Balwani, Nachiket Shevale, Jingwei Sun, Erica Del Aguila, Srijani Sridhar, Nishit Patel, Daniel O’Connell, Reynald Lescarbeau, Birgit Schultes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/78f4ef7a2bb1478bac10a1d8313943d7
Autor:
Eliana Ruggiero, Erica Carnevale, Aaron Prodeus, Zulma Irene Magnani, Barbara Camisa, Ivan Merelli, Claudia Politano, Lorena Stasi, Alessia Potenza, Beatrice Claudia Cianciotti, Francesco Manfredi, Mattia Di Bono, Luca Vago, Michela Tassara, Sara Mastaglio, Maurilio Ponzoni, Francesca Sanvito, Dai Liu, Ishina Balwani, Rossella Galli, Marco Genua, Renato Ostuni, Matteo Doglio, Daniel O’Connell, Ivy Dutta, Stephanie Ann Yazinski, Mark McKee, Mohamed Simo Arredouani, Birgit Schultes, Fabio Ciceri, Chiara Bonini
Publikováno v:
Science translational medicine 14 (2022). doi:10.1126/scitranslmed.abg8027
info:cnr-pdr/source/autori:Ruggiero, Eliana; Carnevale, Erica; Prodeus, Aaron; Magnani, Zulma Irene; Camisa, Barbara; Merelli, Ivan; Politano, Claudia; Stasi, Lorena; Potenza, Alessia; Cianciotti, Beatrice Claudia; Manfredi, Francesco; Di Bono, Mattia; Vago, Luca; Tassara, Michela; Mastaglio, Sara; Ponzoni, Maurilio; Sanvito, Francesca; Liu, Dai; Balwani, Ishina; Galli, Rossella; Genua, Marco; Ostuni, Renato; Doglio, Matteo; O'Connell, Daniel; Dutta, Ivy; Yazinski, Stephanie Ann; McKee, Mark; Arredouani, Mohamed Simo; Schultes, Birgit; Ciceri, Fabio; Bonini, Chiara/titolo:CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function/doi:10.1126%2Fscitranslmed.abg8027/rivista:Science translational medicine/anno:2022/pagina_da:/pagina_a:/intervallo_pagine:/volume:14
info:cnr-pdr/source/autori:Ruggiero, Eliana; Carnevale, Erica; Prodeus, Aaron; Magnani, Zulma Irene; Camisa, Barbara; Merelli, Ivan; Politano, Claudia; Stasi, Lorena; Potenza, Alessia; Cianciotti, Beatrice Claudia; Manfredi, Francesco; Di Bono, Mattia; Vago, Luca; Tassara, Michela; Mastaglio, Sara; Ponzoni, Maurilio; Sanvito, Francesca; Liu, Dai; Balwani, Ishina; Galli, Rossella; Genua, Marco; Ostuni, Renato; Doglio, Matteo; O'Connell, Daniel; Dutta, Ivy; Yazinski, Stephanie Ann; McKee, Mark; Arredouani, Mohamed Simo; Schultes, Birgit; Ciceri, Fabio; Bonini, Chiara/titolo:CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function/doi:10.1126%2Fscitranslmed.abg8027/rivista:Science translational medicine/anno:2022/pagina_da:/pagina_a:/intervallo_pagine:/volume:14
T cell receptor (TCR)–based therapy has the potential to induce durable clinical responses in patients with cancer by targeting intracellular tumor antigens with high sensitivity and by promoting T cell survival. However, the need for TCRs specific
Autor:
Birgit Schultes, Troy Luster, Daniel O’Connell, Jeffrey Jones, Erica Del Aguila, Nishit Patel, Srijani Sridhar, Jingwei Sun, Nachiket Shevale, Amy Melissa Becker, Ishina Balwani, Reynald Lescarbeau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptor (CAR)-based T cell therapy and other forms of adoptive cell therapies (ACTs) have shown remarkable success in the treatment of hematologic malignancies; however, reports of clinical activity in solid tumors are li
Autor:
Lukasz J. Ochyl, Minzhi Yu, Ishina Balwani, Alireza Hassani Najafabadi, Yao Xu, Rui Kuai, Xiaoqi Sun, Lindsay Scheetz, Wenmin Yuan, Anna Schwendeman, James J. Moon
Publikováno v:
Journal of Controlled Release. 282:131-139
Recent studies have shown that certain combinations of Toll-like receptor (TLR) agonists can induce synergistic immune activation. However, it remains challenging to achieve such robust responses in vivo in a manner that is effective, facile, and ame
Autor:
Utsav Jetley, Daniel O′Connell, Reynald Lescarbeau, Surbhi Goel, Birgit Schultes, Marie Keenan, Palak Sharma, Simo M Arredouani, Priya Venkatesan, John Averill, Yiyang Tan, Ishina Balwani, Matthew Roy, Utkarsha Ranade, Ivy Dutta, Yong Zhang, Dai Liu, Aaron Prodeus
Publikováno v:
Blood. 138:1711-1711
Introduction. Despite the success of autologous chimeric antigen receptor (CAR)-T cells, barriers to a more widespread use of this potentially curative therapy include manufacturing failures and the high cost of individualized production. There is a
Publikováno v:
Biocatalysis and Agricultural Biotechnology. 12:23-29
Focusing towards sustainable and environment friendly agricultural techniques, phytase enzymes have proved to be beneficial in many aspects. It is a group of enzymes, which are capable of degrading phosphate containing organic molecules, henceforth r
Autor:
Aaron Prodeus, Amy M. Becker, Laura Sepp-Lorenzino, Maxwell Foisey, Birgit Schultes, Mark D. McKee, Simo M Arredouani, Eliana Ruggiero, Chiara Bonini, Ishina Balwani, Fabio Ciceri, Ivy Dutta, Qingzhan Zhang, Dai Liu
Publikováno v:
Blood. 136:32-33
Adoptive cell therapy using T cells expressing transgenic (tg) tumor antigen-targeting T cell receptors (TCRs) has become an attractive modality to treat hematological and solid cancers due to a broader array of accessible targets relative to CAR-T c
Autor:
Jeffrey Jones, Christopher Rudulier, Minasri Borah, Utsav Jetley, Terina Martinez, Vandhana Ragothaman, Marie Keenan, Yong Zhang, Yuko Miki, Birgit Schultes, Elizabeth McMichael, Amanda Frain, Ishina Balwani, Priya Pajanirassa, Troy A. Luster, Nicole Ganci
Publikováno v:
Cancer Research. 80:5574-5574
The implementation of various mouse models is critical to asses safety, efficacy, and short- and long-term persistence of therapeutic modalities, especially for cell-based therapies. To increase our repertoire of viable humanized murine models, we de